WHO WE ARE
We provide sustainable bio-engineering solutions through bacteriophage Innovation.
WHO WE ARE
We provide sustainable bio-engineering solutions through bacteriophage Innovation.
As a National High-Tech Enterprise with global scientific ambitions, we pioneer bacteriophage-based ecosystem solutions that redefine sustainable agriculture and healthcare. Our vertically integrated platform synergizes precision strain selection, green biomanufacturing, and circular application systems to address critical challenges in antibiotic resistance reduction and environmental stewardship.
Scientific Synergy for Planetary Health
Through strategic alliances with the National Key Laboratory of Agricultural Microbial Resources (Huazhong Agricultural University) and the State Key Laboratory of Biocatalysis & Enzyme Engineering (Hubei University), we have developed China's largest phage repository and host strain bank. Our collaborations extend to global sustainability initiatives, focusing on:
• Microbial resource preservation for biodiversity conservation
• Low-carbon bioproduction process development
• Closed-loop phage application systems minimizing ecological footprint
Sustainable Development
✓ Recycle 95% of fermentation byproducts by 2026
✓ Train 10,000 farmers in sustainable phage applications by 2027
✓ Achieve carbon-neutral production by 2028
Sustainable Product Ecosystem
Our five strategic verticals deliver science-based sustainability:
1. Livestock Health: Phage alternatives reducing 70%+ antibiotic use in farming
2. Aquatic Biosolutions: Non-chemical disease control preserving marine ecosystems
3. Plant Protection: Targeted biocontrol agents eliminating pesticide residues
4. Food Safety: Natural preservatives cutting food waste by 30% in supply chains
5. Consumer Healthcare: Probiotic-phage synergies promoting microbiome health
Sustainability-Driven Honors
• United Nations Environmental Conventions Participant
• National Green Manufacturing Demonstration Unit (2023)
• Hubei Circular Economy Pioneer Enterprise
• Patent Portfolio Focused on Environmental Biotechnology
How We Do It
Our vision is to be the most trusted and valued animal health company, shaping the future of animal care through our innovation, customer obsession and purpose-driven colleagues. Our future performance is focused on 6 strategic priorities:
Lead Through Innovation Across Our Diverse Portfolio
Deliver an Exceptional Experience to Delight Our Customers
Power Our Business Through Digital Solutions and Data Insights
Support a Workplace Where Our Colleagues Can Thrive
Advance Sustainability in Animal Health for a Better Future
Perform with Excellence and Agility
Innovation Engineered for Tomorrow
Our 50+ member R&D cohort integrates ecological wisdom with cutting-edge science:
• 5 Professors specializing in biology
• 2 senior system engineers
• 40+ PhD research and development teams
• 80+ Patents including 12 Green Technology Patents
Sustainability Commitment
We pledge to:
✓ Recycle 95% of fermentation byproducts by 2026
✓ Train 10,000 farmers in sustainable phage applications by 2027
✓ Achieve carbon-neutral production by 2028
Vision & Value
Intelligent Empowerment for One Health Ecosystem
Pioneering bacteriophage-based solutions that synergistically advance human, animal, and environmental health through transformative biotechnology.
Global Vision & Guiding Principles
Architecting the Future of Precision Bioeconomy
Mission
Intelligent Empowerment for One Health Ecosystem
Pioneering bacteriophage-based solutions that synergistically advance human, animal, and environmental health through transformative biotechnology.
Vision
The Global Biomanufacturing Ecosystem Nexus
Establishing the world's most interconnected phage technology matrix, connecting 50+ nations through:
✓ Next-gen antimicrobial manufacturing standards
✓ Transcontinental biofoundry networks
✓ AI-driven phage discovery infrastructure
Core Values
Inclusive Synergy | Strategic Co-Creation | Global Commons
• Inclusive Synergy: Integrating 15+ disciplinary wisdom across 6 time zones
• Strategic Co-Creation: 30+ industry-academic consortia with MIT Bioengineering, EU Horizon Pharma 2030
• Global Commons:Open-source sharing of 20% non-core IP through WHO technology transfer pools
Cultural DNA of Innovation
1. Frontier Innovation Culture
Our global R&D constellation drives industry paradigm shifts:
Phage 4.0 Initiative: Merging synthetic biology with quantum computing (3 ongoing ERC grants)
Transnational IP Matrix:
• 12 PCT patents under WIPO GREEN program
• 5 FDA Breakthrough Therapy designations
Living Lab Network:
• Joint innovation centers with Imperial College London (UK)
• NSF-funded phage engineering hub (Boston)
2. Ecosystem Collaboration Culture
Building the world's smartest bio-alliance:
✓ Industrial Symbiosis: Co-developing solutions with 7 Fortune 500 animal health corporations
✓ Bio-Cluster Leadership: Founding member of International Phage Alliance (23 nations)
✓ Digital Co-Working: Real-time R&D coordination across Wuhan-San Diego-Basel hubs via proprietary BioOS platform
3. Planetary Stewardship Culture
Redefining biotechnology ethics:
• Antibiotic Reduction Index: Enabled 53% decrease in veterinary antibiotic use across partner farms
• Global Green Pledge:
• Signatory to Science Based Targets initiative (SBTi)
• 100% renewable energy in EU operations by 2025
• One Health Impact:
• 12 peer-reviewed studies in Lancet Planetary Health
• Technical advisor to FAO Antimicrobial Resistance Action Group
4. Wisdom Integration Culture
Perpetual learning ecosystem:
Global Faculty Program: Rotating professorships with ETH Zurich and UC Berkeley
Phage Future Forum: Annual knowledge summit attracting 300+ international experts
Competency Cloud:
• 40% staff holding dual-domain expertise
• 150+ certified courses on Coursera/Udemy
• 92% R&D team presenting at international congresses annually
Strategic Differentiation
✓ Glocalization Engine: Localized production units with global quality control (8 ISO certifications)
✓ Bio-Diplomacy: Technical ambassador to BRICS New Industrial Revolution Partnership
✓ Future-Proof Pipeline: 35% R&D budget allocated to 2030+ frontier technologies
Global Exclusive Agent: Handee Green Biotech Co.,Ltd
